160 related articles for article (PubMed ID: 25888435)
1. Synthetic lethals in HIV: ways to avoid drug resistance : Running title: Preventing HIV resistance.
Petitjean M; Badel A; Veitia RA; Vanet A
Biol Direct; 2015 Apr; 10():17. PubMed ID: 25888435
[TBL] [Abstract][Full Text] [Related]
2. Co-lethality studied as an asset against viral drug escape: the HIV protease case.
Brouillet S; Valere T; Ollivier E; Marsan L; Vanet A
Biol Direct; 2010 Jun; 5():40. PubMed ID: 20565756
[TBL] [Abstract][Full Text] [Related]
3. Protein promiscuity: drug resistance and native functions--HIV-1 case.
Fernández A; Tawfik DS; Berkhout B; Sanders R; Kloczkowski A; Sen T; Jernigan B
J Biomol Struct Dyn; 2005 Jun; 22(6):615-24. PubMed ID: 15842167
[TBL] [Abstract][Full Text] [Related]
4. Analysis of discrepancies in the interpretation of antiretroviral drug resistance results in HIV-1 infected patients of Basque Country, Spain.
Muñoz M; Carmona R; Pérez-Alvarez L; Cilla G; Suarez MD; Delgado E; Contreras G; Corral J; de Goicoetxea MJ; Medrano L; Lezaún MJ; Nájera R;
J Clin Virol; 2005 Jul; 33(3):224-9. PubMed ID: 15911444
[TBL] [Abstract][Full Text] [Related]
5. Natural polymorphism in protease and reverse transcriptase genes and in vitro antiretroviral drug susceptibilities of non-B HIV-1 strains from treatment-naive patients.
Vergne L; Stuyver L; Van Houtte M; Butel C; Delaporte E; Peeters M
J Clin Virol; 2006 May; 36(1):43-9. PubMed ID: 16563858
[TBL] [Abstract][Full Text] [Related]
6. Sustained appearance of drug resistance-associated mutations in HIV-1 CRF01_AE protease and reverse transcriptase derived from protease inhibitor-naive Thai patients.
Jullaksorn D; Boonchawalit S; Uttiyoung J; Soonthornsata B; Yowang A; Krathong N; Chautrakul S; Ikuta K; Roobsoong A; Kanitvittaya S; Sawanpanyalert P; Kameoka M
Southeast Asian J Trop Med Public Health; 2010 Mar; 41(2):347-57. PubMed ID: 20578518
[TBL] [Abstract][Full Text] [Related]
7. Appearance of drug resistance-associated mutations in human immunodeficiency virus type 1 protease and reverse transcriptase derived from drug-treated Indonesian patients.
Khairunisa SQ; Kotaki T; Witaningrum AM; Yunifiar M MQ; Sukartiningrum SD; Nasronudin ; Kameoka M
AIDS Res Hum Retroviruses; 2015 Feb; 31(2):255-9. PubMed ID: 25348045
[TBL] [Abstract][Full Text] [Related]
8. Natural residues versus antiretroviral drug-selected mutations in HIV type 1 group O reverse transcriptase and protease related to virological drug failure in vivo.
de Baar MP; Janssens W; de Ronde A; Fransen K; Colebunders R; Kestens L; van der Groen G; Goudsmit J
AIDS Res Hum Retroviruses; 2000 Sep; 16(14):1385-94. PubMed ID: 11018858
[TBL] [Abstract][Full Text] [Related]
9. Use of evolutionary limitations of HIV-1 multidrug resistance to optimize therapy.
Chow YK; Hirsch MS; Merrill DP; Bechtel LJ; Eron JJ; Kaplan JC; D'Aquila RT
Nature; 1993 Feb; 361(6413):650-4. PubMed ID: 7679778
[TBL] [Abstract][Full Text] [Related]
10. Limited increase in primary HIV-1C drug resistance mutations in treatment naïve individuals in Ethiopia.
Huruy K; Maier M; Mulu A; Liebert UG
J Med Virol; 2015 Jun; 87(6):978-84. PubMed ID: 25649964
[TBL] [Abstract][Full Text] [Related]
11. Structural mechanisms of HIV drug resistance.
Erickson JW; Burt SK
Annu Rev Pharmacol Toxicol; 1996; 36():545-71. PubMed ID: 8725401
[TBL] [Abstract][Full Text] [Related]
12. A hierarchical model of HIV-1 protease drug resistance.
Goodsell DS
Appl Bioinformatics; 2002; 1(1):3-12. PubMed ID: 15130852
[TBL] [Abstract][Full Text] [Related]
13. Evidence of differential selection of HIV-1 variants carrying drug-resistant mutations in seroconverters.
Corvasce S; Violin M; Romano L; Razzolini F; Vicenti I; Galli A; Duca P; Caramma I; Balotta C; Zazzi M
Antivir Ther; 2006; 11(3):329-34. PubMed ID: 16759049
[TBL] [Abstract][Full Text] [Related]
14. Evolutionary analysis of HIV-1 protease inhibitors: Methods for design of inhibitors that evade resistance.
Stoffler D; Sanner MF; Morris GM; Olson AJ; Goodsell DS
Proteins; 2002 Jul; 48(1):63-74. PubMed ID: 12012338
[TBL] [Abstract][Full Text] [Related]
15. Mutation covariation of HIV-1 CRF07_BC reverse transcriptase during antiretroviral therapy.
Li Z; Huang Y; Ouyang Y; Xing H; Liao L; Jiang S; Shao Y; Ma L
J Antimicrob Chemother; 2013 Nov; 68(11):2521-4. PubMed ID: 23788482
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of drug-resistance-associated mutations in antiretroviral drug-naive Zambians infected with subtype C HIV-1.
Handema R; Terunuma H; Kasolo F; Kasai H; Sichone M; Yamashita A; Deng X; Mulundu G; Ichiyama K; Munkanta M; Yokota T; Wakasugi N; Tezuka F; Yamamoto N; Ito M
AIDS Res Hum Retroviruses; 2003 Feb; 19(2):151-60. PubMed ID: 12643279
[TBL] [Abstract][Full Text] [Related]
17. HIV-1 genotyping of the protease-reverse transcriptase and integrase genes to detect mutations that confer antiretroviral resistance.
Van den Eede P; Van Wesenbeeck L; Verlinden Y; Feyaerts M; Smits V; Verheyen A; Vanhooren L; Deloof A; Villacian J; Pattery T
Methods Mol Biol; 2013; 1030():37-55. PubMed ID: 23821259
[TBL] [Abstract][Full Text] [Related]
18. Analysis of protease and reverse transcriptase genes of HIV for antiretroviral drug resistance in Jamaican adults.
Hamilton CL; Eyzaguirre LM; Amarakoon II; Figueroa P; Duncan J; Carr JK; Roye ME
AIDS Res Hum Retroviruses; 2012 Aug; 28(8):923-7. PubMed ID: 22049946
[TBL] [Abstract][Full Text] [Related]
19. Rapid detection of drug resistant HIV -1 to reverse transcriptase and protease inhibitors in HIV-infected patients receiving highly active antiretroviral therapies.
Yu M; Kabat W; Wang J
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Dec; 14(4):325-9. PubMed ID: 11471017
[TBL] [Abstract][Full Text] [Related]
20. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
Van Vaerenbergh K
Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
